|
US3993073A
(en)
|
1969-04-01 |
1976-11-23 |
Alza Corporation |
Novel drug delivery device
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3598122A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4069307A
(en)
|
1970-10-01 |
1978-01-17 |
Alza Corporation |
Drug-delivery device comprising certain polymeric materials for controlled release of drug
|
|
US3731683A
(en)
|
1971-06-04 |
1973-05-08 |
Alza Corp |
Bandage for the controlled metering of topical drugs to the skin
|
|
US3996934A
(en)
|
1971-08-09 |
1976-12-14 |
Alza Corporation |
Medical bandage
|
|
US3742951A
(en)
|
1971-08-09 |
1973-07-03 |
Alza Corp |
Bandage for controlled release of vasodilators
|
|
BE795384A
(fr)
|
1972-02-14 |
1973-08-13 |
Ici Ltd |
Pansements
|
|
US3921636A
(en)
|
1973-01-15 |
1975-11-25 |
Alza Corp |
Novel drug delivery device
|
|
US3993072A
(en)
|
1974-08-28 |
1976-11-23 |
Alza Corporation |
Microporous drug delivery device
|
|
US4151273A
(en)
|
1974-10-31 |
1979-04-24 |
The Regents Of The University Of California |
Increasing the absorption rate of insoluble drugs
|
|
US3972995A
(en)
|
1975-04-14 |
1976-08-03 |
American Home Products Corporation |
Dosage form
|
|
US4077407A
(en)
|
1975-11-24 |
1978-03-07 |
Alza Corporation |
Osmotic devices having composite walls
|
|
US4031894A
(en)
|
1975-12-08 |
1977-06-28 |
Alza Corporation |
Bandage for transdermally administering scopolamine to prevent nausea
|
|
US4060084A
(en)
|
1976-09-07 |
1977-11-29 |
Alza Corporation |
Method and therapeutic system for providing chemotherapy transdermally
|
|
US4201211A
(en)
|
1977-07-12 |
1980-05-06 |
Alza Corporation |
Therapeutic system for administering clonidine transdermally
|
|
JPS5562012A
(en)
|
1978-11-06 |
1980-05-10 |
Teijin Ltd |
Slow-releasing preparation
|
|
US4230105A
(en)
|
1978-11-13 |
1980-10-28 |
Merck & Co., Inc. |
Transdermal delivery of drugs
|
|
US4229447A
(en)
|
1979-06-04 |
1980-10-21 |
American Home Products Corporation |
Intraoral methods of using benzodiazepines
|
|
CA1146866A
(en)
|
1979-07-05 |
1983-05-24 |
Yamanouchi Pharmaceutical Co. Ltd. |
Process for the production of sustained release pharmaceutical composition of solid medical material
|
|
US4291015A
(en)
|
1979-08-14 |
1981-09-22 |
Key Pharmaceuticals, Inc. |
Polymeric diffusion matrix containing a vasodilator
|
|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4596795A
(en)
|
1984-04-25 |
1986-06-24 |
The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services |
Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
GB8518301D0
(en)
|
1985-07-19 |
1985-08-29 |
Fujisawa Pharmaceutical Co |
Hydrodynamically explosive systems
|
|
US5011692A
(en)
|
1985-12-28 |
1991-04-30 |
Sumitomo Pharmaceuticals Company, Limited |
Sustained pulsewise release pharmaceutical preparation
|
|
US4755386A
(en)
|
1986-01-22 |
1988-07-05 |
Schering Corporation |
Buccal formulation
|
|
US5312325A
(en)
|
1987-05-28 |
1994-05-17 |
Drug Delivery Systems Inc |
Pulsating transdermal drug delivery system
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
US5739136A
(en)
|
1989-10-17 |
1998-04-14 |
Ellinwood, Jr.; Everett H. |
Intraoral dosing method of administering medicaments
|
|
US5017381A
(en)
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
|
US5633009A
(en)
|
1990-11-28 |
1997-05-27 |
Sano Corporation |
Transdermal administration of azapirones
|
|
WO1992018106A1
(fr)
|
1991-04-16 |
1992-10-29 |
Nippon Shinyaku Co., Ltd. |
Procede de production d'une dispersion solide
|
|
HU227530B1
(en)
|
1991-11-22 |
2011-07-28 |
Warner Chilcott Company |
Delayed-release compositions containing risedronate and process for their production
|
|
US5229135A
(en)
|
1991-11-22 |
1993-07-20 |
Prographarm Laboratories |
Sustained release diltiazem formulation
|
|
US5340591A
(en)
|
1992-01-24 |
1994-08-23 |
Fujisawa Pharmaceutical Co., Ltd. |
Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5260068A
(en)
|
1992-05-04 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Multiparticulate pulsatile drug delivery system
|
|
US5281420A
(en)
|
1992-05-19 |
1994-01-25 |
The Procter & Gamble Company |
Solid dispersion compositions of tebufelone
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
AU4198793A
(en)
|
1992-07-24 |
1994-01-27 |
Takeda Chemical Industries Ltd. |
Microparticle preparation and production thereof
|
|
US5700485A
(en)
|
1992-09-10 |
1997-12-23 |
Children's Medical Center Corporation |
Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
|
|
JP2616252B2
(ja)
|
1992-10-16 |
1997-06-04 |
日本新薬株式会社 |
ワックスマトリックスの製法
|
|
US5260069A
(en)
|
1992-11-27 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Pulsatile particles drug delivery system
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US5665378A
(en)
|
1994-09-30 |
1997-09-09 |
Davis; Roosevelt |
Transdermal therapeutic formulation
|
|
US5567441A
(en)
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
SE9502244D0
(sv)
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
|
US5837284A
(en)
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
|
US6923983B2
(en)
|
1996-02-19 |
2005-08-02 |
Acrux Dds Pty Ltd |
Transdermal delivery of hormones
|
|
US6929801B2
(en)
|
1996-02-19 |
2005-08-16 |
Acrux Dds Pty Ltd |
Transdermal delivery of antiparkinson agents
|
|
US6458373B1
(en)
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
US5869090A
(en)
|
1998-01-20 |
1999-02-09 |
Rosenbaum; Jerry |
Transdermal delivery of dehydroepiandrosterone
|
|
US6946144B1
(en)
|
1998-07-08 |
2005-09-20 |
Oryxe |
Transdermal delivery system
|
|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
ES2208364T3
(es)
|
1999-07-16 |
2004-06-16 |
Warner-Lambert Company Llc |
Procedimiento para tratar dolor cronico usando inhibidores de mek.
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
JP2002309116A
(ja)
|
2001-04-09 |
2002-10-23 |
Fuji Photo Film Co Ltd |
アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
|
|
KR100601774B1
(ko)
|
2001-04-09 |
2006-07-19 |
후지 샤신 필름 가부시기가이샤 |
화상 형성용 착색 조성물 및 칼라 화상의 내오존성 개선방법
|
|
JP4406515B2
(ja)
|
2001-04-09 |
2010-01-27 |
富士フイルム株式会社 |
アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
|
|
US6960563B2
(en)
|
2001-08-31 |
2005-11-01 |
Morton Grove Pharmaceuticals, Inc. |
Spontaneous emulsions containing cyclosporine
|
|
JP2003292859A
(ja)
|
2002-01-30 |
2003-10-15 |
Fuji Photo Film Co Ltd |
インク組成物、インクジェット記録方法
|
|
JP3844338B2
(ja)
|
2002-02-01 |
2006-11-08 |
富士写真フイルム株式会社 |
インクセット、インクカートリッジ、記録方法、プリンター及び記録物
|
|
JP2004059687A
(ja)
|
2002-07-26 |
2004-02-26 |
Fuji Photo Film Co Ltd |
着色組成物、インクジェット記録用インク、インクジェット記録方法、感熱記録材料、カラートナー、およびカラーフィルター
|
|
JP4213922B2
(ja)
|
2002-08-12 |
2009-01-28 |
富士フイルム株式会社 |
インクジェット記録用インク及びインクセット、並びにインクジェット記録方法
|
|
JP2004083610A
(ja)
|
2002-08-22 |
2004-03-18 |
Fuji Photo Film Co Ltd |
インクセット、インクカートリッジ、記録方法、プリンター及び記録物
|
|
JP2004099802A
(ja)
|
2002-09-11 |
2004-04-02 |
Fuji Photo Film Co Ltd |
画像形成用着色組成物、インクジェット記録用インクおよびインクジェット記録方法
|
|
JP4895341B2
(ja)
|
2004-07-08 |
2012-03-14 |
富士フイルム株式会社 |
アゾ色素、インクジェット記録用インク、感熱記録材料、カラートナー、カラーフィルター、インクジェット記録方法、インクカートリッジ及びインクジェットプリンター
|
|
WO2007085638A1
(en)
|
2006-01-26 |
2007-08-02 |
Boehringer Ingelheim International Gmbh |
Process for preparing aminocrotonylamino-substituted quinazoline derivatives
|
|
JP2007203642A
(ja)
|
2006-02-02 |
2007-08-16 |
Fujifilm Corp |
インクジェット記録用セット、及びインクジェット記録方法
|
|
JP2008013499A
(ja)
|
2006-07-06 |
2008-01-24 |
Sankyo Co Ltd |
５−シアノニコチンアミド誘導体
|
|
US7741385B2
(en)
|
2006-10-31 |
2010-06-22 |
Hewlett-Packard Development Company, L.P. |
Ozone stable ink-jet inks
|
|
JP2009139810A
(ja)
|
2007-12-10 |
2009-06-25 |
Konica Minolta Business Technologies Inc |
電子写真用トナー
|
|
LT3009428T
(lt)
|
2009-05-08 |
2018-04-10 |
Astellas Pharma Inc. |
Diamino heterociklinis karboksamido junginys
|
|
NZ595705A
(en)
|
2009-05-18 |
2013-01-25 |
Orion Corp |
Protease inhibitors
|
|
AR078173A1
(es)
|
2009-09-15 |
2011-10-19 |
Sanofi Aventis |
Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
|
|
ES2689103T3
(es)
|
2010-06-30 |
2018-11-08 |
Fujifilm Corporation |
Nuevo derivado de nicotinamida o sal del mismo
|
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
|
CA2816219C
(en)
|
2010-11-01 |
2019-10-29 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as syk modulators
|
|
EP2799431B1
(en)
|
2011-12-28 |
2018-01-24 |
FUJIFILM Corporation |
Novel nicotinamide derivative or salt thereof
|
|
EA026353B1
(ru)
|
2012-01-17 |
2017-03-31 |
Астеллас Фарма Инк. |
Соединение пиразинкарбоксамида
|
|
US8877763B2
(en)
|
2012-03-22 |
2014-11-04 |
Genosco |
Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
|
|
HRP20180037T1
(hr)
|
2012-04-17 |
2018-03-23 |
Fujifilm Corporation |
Heterociklični spoj koji sadrži dušik ili njegovu sol
|
|
WO2014012467A1
(zh)
|
2012-07-20 |
2014-01-23 |
中国人民解放军军事医学科学院毒物药物研究所 |
间二芳基苯胺类或吡啶胺类化合物、其制备方法及医药用途
|
|
KR101744033B1
(ko)
|
2013-10-16 |
2017-06-07 |
후지필름 가부시키가이샤 |
함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
|
|
WO2015062929A1
(en)
|
2013-10-29 |
2015-05-07 |
Dystar Colours Distribution Gmbh |
Acid dyes, process for the production thereof and their use
|
|
EP2868709A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Metal free acid dyes, process for the production thereof and their use
|
|
EP2868710A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Metal free acid dyes, process for the production thereof and their use
|
|
US20200332369A1
(en)
|
2014-01-27 |
2020-10-22 |
Dna-Seq, Inc. |
Methods and systems for determination of an effective therapeutic regimen and drug discovery
|
|
US11045468B2
(en)
|
2014-02-04 |
2021-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
|
|
MA39908A
(fr)
|
2014-05-28 |
2015-12-03 |
Astellas Pharma Inc |
Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif
|
|
US10065934B2
(en)
|
2014-07-17 |
2018-09-04 |
Sunshine Lake Pharma Co., Ltd. |
Substituted urea derivatives and pharmaceutical uses thereof
|
|
CN105294682B
(zh)
|
2014-07-26 |
2017-07-07 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
WO2016015605A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
|
CN105439879B
(zh)
|
2014-08-07 |
2018-08-10 |
天津法莫西医药科技有限公司 |
一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
|
|
EP3181553B1
(en)
|
2014-08-15 |
2019-12-11 |
Arromax Pharmatech Co., Ltd. |
Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
|
|
EP3195866B1
(en)
|
2014-08-22 |
2020-11-18 |
FUJIFILM Corporation |
Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
|
|
US10876176B2
(en)
|
2014-12-18 |
2020-12-29 |
Aravive Biologics, Inc. |
Antifibrotic activity of GAS6 inhibitor
|
|
KR20170105021A
(ko)
|
2015-01-28 |
2017-09-18 |
아스테라스 세이야쿠 가부시키가이샤 |
피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
|
|
MX2017013788A
(es)
|
2015-04-27 |
2018-03-27 |
Astellas Pharma Inc |
Composicion farmaceutica estabilizada.
|
|
JP2018104290A
(ja)
|
2015-04-28 |
2018-07-05 |
アステラス製薬株式会社 |
ピラジンカルボキサミド化合物を有効成分とする医薬組成物
|
|
CN106267234B
(zh)
|
2015-06-26 |
2020-04-10 |
上海市计划生育科学研究所 |
含有非核苷类逆转录酶抑制剂的阴道环及其制备方法
|
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
EP3318259B1
(en)
|
2015-07-03 |
2023-01-11 |
Astellas Pharma Inc. |
Stable pharmaceutical composition for oral administration
|
|
JP6412471B2
(ja)
|
2015-07-15 |
2018-10-24 |
富士フイルム株式会社 |
含窒素複素環化合物の製造方法およびその中間体
|
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
|
US10308658B2
(en)
|
2015-10-19 |
2019-06-04 |
Sunshine Lake Pharma Co., Ltd. |
Salt of EGFR inhibitor, crystalline form and uses thereof
|
|
WO2017078049A1
(ja)
|
2015-11-04 |
2017-05-11 |
アステラス製薬株式会社 |
ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物
|
|
US10927418B2
(en)
|
2015-11-11 |
2021-02-23 |
Celator Pharmaceuticals, Inc. |
Assays and methods for selecting a treatment regimen for a subject with leukemia
|
|
JP6905662B2
(ja)
|
2015-11-14 |
2021-07-21 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． |
置換キノリン化合物の結晶形およびその医薬組成物
|
|
EP3373932B1
(en)
|
2015-11-14 |
2022-03-30 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
JP2019014653A
(ja)
|
2015-11-27 |
2019-01-31 |
アステラス製薬株式会社 |
がん免疫を介したがん治療方法
|
|
TWI623316B
(zh)
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
MA43640A
(fr)
|
2016-02-26 |
2018-11-28 |
Agios Pharmaceuticals Inc |
Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
|
|
CA3018155A1
(en)
|
2016-03-29 |
2017-10-05 |
Astellas Pharma Inc. |
Combination therapy for the treatment of acute myeloid leukemia
|
|
CA3021021A1
(en)
|
2016-04-15 |
2017-10-19 |
Felicitex Therapeutics, Inc. |
Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
WO2017214433A1
(en)
|
2016-06-09 |
2017-12-14 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
|
|
WO2017218365A1
(en)
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
CN106083821B
(zh)
|
2016-06-22 |
2019-01-11 |
上海皓元生物医药科技有限公司 |
一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
|
|
AU2017302635B2
(en)
|
2016-07-29 |
2021-09-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
US10246462B2
(en)
|
2016-09-09 |
2019-04-02 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
|
AU2017325844A1
(en)
|
2016-09-14 |
2019-03-07 |
Gilead Sciences, Inc. |
SYK inhibitors
|
|
US11672801B2
(en)
|
2016-10-19 |
2023-06-13 |
United States Government As Represented By The Department Of Veterans Affairs |
Compositions and methods for treating cancer
|
|
WO2018079570A1
(ja)
|
2016-10-26 |
2018-05-03 |
アステラス製薬株式会社 |
安定な医薬組成物
|
|
CN106589055B
(zh)
|
2016-11-03 |
2020-07-28 |
清华大学 |
取代的细胞酰二肽类化合物及其制备方法和用途
|
|
AR110273A1
(es)
|
2016-11-30 |
2019-03-13 |
Pharmacyclics Llc |
Inhibidores de tirosina cinasa de bruton
|
|
WO2018103663A1
(zh)
|
2016-12-09 |
2018-06-14 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
|
|
CN108250200A
(zh)
|
2016-12-28 |
2018-07-06 |
中国科学院上海药物研究所 |
一种具有Axl抑制活性的化合物及其制备和应用
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
TWI821174B
(zh)
|
2017-02-21 |
2023-11-11 |
加拿大商艾普托斯生物科學公司 |
治療血液惡性腫瘤患者的方法
|
|
GB201704267D0
(en)
|
2017-03-17 |
2017-05-03 |
Genome Res Ltd |
Novel biomarker
|
|
WO2018175251A1
(en)
|
2017-03-20 |
2018-09-27 |
Celcuity Llc |
Methods of measuring signaling pathway activity for selection of therapeutic agents
|
|
WO2018183762A1
(en)
|
2017-03-29 |
2018-10-04 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating cancer
|
|
JP6617208B2
(ja)
|
2017-03-31 |
2019-12-11 |
ノバルティス アーゲー |
血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
CN110621316B
(zh)
|
2017-04-21 |
2024-01-26 |
Epizyme股份有限公司 |
用ehmt2抑制剂进行的组合疗法
|
|
US11702469B2
(en)
|
2017-04-24 |
2023-07-18 |
Ohio State Innovation Foundation |
Recombinant EGFL7, EGFL7 antibodies, and uses thereof
|
|
US10857144B2
(en)
|
2017-05-16 |
2020-12-08 |
Bow River LLC |
Methods of treatment
|
|
JP2020519665A
(ja)
|
2017-05-17 |
2020-07-02 |
アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） |
オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤
|
|
MY201312A
(en)
|
2017-06-02 |
2024-02-16 |
Pfizer |
Antibodies specific for flt3 and their uses
|
|
CA3069558A1
(en)
|
2017-07-09 |
2019-01-17 |
Biosight Ltd. |
Combination cancer therapy
|
|
CN109251182A
(zh)
|
2017-07-13 |
2019-01-22 |
广东东阳光药业有限公司 |
取代脲衍生物的盐及其在药物中的应用
|
|
CN111182903A
(zh)
|
2017-07-28 |
2020-05-19 |
特普医药公司 |
巨环化合物及其用途
|
|
US20200197385A1
(en)
|
2017-08-23 |
2020-06-25 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for cancer containing axl inhibitor as active ingredient
|
|
EP3687542A1
(en)
|
2017-09-27 |
2020-08-05 |
AI Therapeutics, Inc. |
Therapeutic methods relating to hsp90 inhibitors
|
|
CA3019207A1
(en)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant egfr signaling
|
|
JP2021500326A
(ja)
|
2017-10-18 |
2021-01-07 |
エピザイム，インコーポレイティド |
血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
|
|
CN111149296B
(zh)
|
2017-10-24 |
2023-09-19 |
京瓷株式会社 |
复合基板以及使用其的弹性波元件
|
|
US11065243B2
(en)
|
2017-10-27 |
2021-07-20 |
Sonic Master Limited |
Inhibitors of DUX4 induction for regulation of muscle function
|
|
US11247990B1
(en)
|
2017-12-07 |
2022-02-15 |
Array Biopharma Inc |
Bicyclic fused pyridine compounds as inhibitors of TAM kinases
|
|
EP3752200A1
(en)
|
2018-02-13 |
2020-12-23 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201802307D0
(en)
|
2018-02-13 |
2018-03-28 |
Vib Vzw |
CD36 antagonists for use in melanoma treatment
|
|
WO2019178267A2
(en)
|
2018-03-13 |
2019-09-19 |
University Of Iowa Research Foundation |
Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
|
|
WO2019184966A1
(zh)
|
2018-03-28 |
2019-10-03 |
深圳市塔吉瑞生物医药有限公司 |
取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
|
|
CN108392634A
(zh)
|
2018-03-28 |
2018-08-14 |
清华大学 |
B7s1抑制剂在制备肝癌药物中的用途
|
|
WO2019197605A2
(en)
|
2018-04-12 |
2019-10-17 |
Umc Utrecht Holding B.V. |
Drug combinations for use in the treatment of ras-mutant cancer
|
|
WO2019245269A1
(ko)
|
2018-06-18 |
2019-12-26 |
연세대학교 산학협력단 |
Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
|
|
WO2020010284A1
(en)
|
2018-07-04 |
2020-01-09 |
Cytoimmune Therapeutics, LLC |
Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
|
|
KR101954370B1
(ko)
|
2018-07-25 |
2019-03-05 |
한미약품 주식회사 |
피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
|
|
TW202019421A
(zh)
|
2018-07-31 |
2020-06-01 |
大陸商蘇州亞盛藥業有限公司 |
Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
|
|
KR20200022712A
(ko)
|
2018-08-23 |
2020-03-04 |
주식회사 오스코텍 |
8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
|
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
|
EP3858819A4
(en)
|
2018-09-30 |
2022-05-18 |
Medshine Discovery Inc. |
3,9-DIAZASPIRO[5,5] UNDECAN COMPOUND AS FLT3 AND AXL INHIBITORS
|
|
TW202027749A
(zh)
|
2018-10-12 |
2020-08-01 |
日商富士軟片股份有限公司 |
急性骨髓性白血病用抗腫瘤劑
|
|
EP3875089A4
(en)
|
2018-10-31 |
2021-12-22 |
FUJIFILM Corporation |
TABLET CONTAINING AN ANTI-TUMOR AGENT
|
|
EP3875091A4
(en)
|
2018-10-31 |
2021-12-29 |
FUJIFILM Corporation |
Pharmaceutical composition containing antitumor agent
|
|
EP3875088A4
(en)
|
2018-10-31 |
2021-12-29 |
FUJIFILM Corporation |
Package for medical composition containing anti-tumor agent
|
|
EP3875090A4
(en)
|
2018-10-31 |
2021-12-22 |
FUJIFILM Corporation |
PELLET CONTAINING AN ANTITUMOR AGENT
|
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
CR20210287A
(es)
|
2018-11-01 |
2022-02-15 |
Syros Pharmaceuticals Inc |
Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
|
|
WO2020118168A1
(en)
|
2018-12-07 |
2020-06-11 |
Cornell University |
Methods for detecting acute myeloid leukemia
|
|
US20200208114A1
(en)
|
2018-12-10 |
2020-07-02 |
The Broad Institute, Inc. |
Taxonomy and use of bone marrow stromal cell
|
|
SG11202105128RA
(en)
|
2018-12-12 |
2021-06-29 |
Agency Science Tech & Res |
Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof
|
|
TWI848030B
(zh)
|
2018-12-18 |
2024-07-11 |
比利時商阿根思公司 |
Ｃｄ７０組合治療
|
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
KR102230721B1
(ko)
|
2019-02-01 |
2021-03-22 |
주식회사 오스코텍 |
피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
|
|
US20220362381A1
(en)
|
2019-02-21 |
2022-11-17 |
Bambu Vault Llc |
Remotely triggered therapy
|
|
WO2020171649A1
(ko)
|
2019-02-22 |
2020-08-27 |
한미약품 주식회사 |
Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
|
|
BR112021016522A2
(pt)
|
2019-02-22 |
2021-10-26 |
Hanmi Pharm. Co., Ltd. |
Composição farmacêutica para o tratamento da leucemia mieloide aguda
|
|
WO2020176686A1
(en)
|
2019-02-26 |
2020-09-03 |
Oregon Health & Science University |
Methods of treating venetoclax-resistant acute myeloid leukemia
|
|
TW202045174A
(zh)
|
2019-02-28 |
2020-12-16 |
日商富士軟片股份有限公司 |
組合醫藥
|
|
ES3040728T3
(en)
|
2019-03-13 |
2025-11-04 |
Otsuka Pharma Co Ltd |
Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
MY204603A
(en)
|
2019-04-03 |
2024-09-05 |
Astellas Pharma Inc |
Pharmaceutical composition
|
|
EP3956035A4
(en)
|
2019-04-17 |
2023-01-25 |
Board of Regents, The University of Texas System |
ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS
|
|
CA3132816A1
(en)
|
2019-04-17 |
2020-10-22 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
|
|
CN113939271B
(zh)
|
2019-04-25 |
2025-04-04 |
视尔普斯眼科公司 |
眼用水凝胶酪氨酸激酶抑制剂植入物
|
|
EP3965896A4
(en)
|
2019-05-09 |
2023-01-25 |
The United States Government as Represented by the Department of Veterans Affairs |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
JP2022537551A
(ja)
|
2019-06-20 |
2022-08-26 |
セルジーン・クオンティセル・リサーチ・インコーポレイテッド |
ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
|
|
EA202290154A1
(ru)
|
2019-06-27 |
2022-03-29 |
Ханми Фарм. Ко., Лтд. |
Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
EP4014047B1
(en)
|
2019-08-14 |
2025-11-19 |
Memorial Sloan Kettering Cancer Center |
Ogdh inhibitors for use in the treatment of cancer
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
BR112022004495A8
(pt)
|
2019-09-12 |
2023-04-18 |
Jiangxi Jemincare Group Co Ltd |
Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
|
|
WO2021076985A1
(en)
|
2019-10-16 |
2021-04-22 |
University Of Virginia Patent Foundation |
Ceramide ratios as predictive and therapeutic biomarkers for leukemias
|
|
IL292378A
(en)
|
2019-10-21 |
2022-06-01 |
Rhizen Pharmaceuticals Ag |
Preparations that include a dhodh inhibitor for the treatment of acute myeloid leukemia
|
|
CN112704679B
(zh)
|
2019-10-24 |
2023-06-06 |
沈阳药科大学 |
含高三尖杉酯碱的药物组合物及其应用
|
|
WO2021087138A1
(en)
|
2019-10-29 |
2021-05-06 |
Syros Pharmaceuticals, Inc. |
Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
JP2022554346A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレーション |
２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
|
|
WO2021092543A1
(en)
|
2019-11-08 |
2021-05-14 |
University Of Virginia Patent Foundation |
Ceramide analog saclac modulates sphingolipid levels and mcl-1 splicing to induce apoptosis in acute myeloid leukemia
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021094827A1
(en)
|
2019-11-11 |
2021-05-20 |
Race Oncology Ltd. |
Use of bisantrene to treat measurable residual disease in acute myeloid leukemia
|
|
CN115151534B
(zh)
|
2020-02-14 |
2024-02-06 |
南京药石科技股份有限公司 |
白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
|
|
WO2021180008A1
(zh)
|
2020-03-11 |
2021-09-16 |
暨南大学 |
含脲结构的三芳环化合物及其应用
|
|
CN111269149B
(zh)
|
2020-04-08 |
2022-04-15 |
南京优氟医药科技有限公司 |
一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺
|
|
CN111358952B
(zh)
|
2020-04-15 |
2022-03-15 |
中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） |
一种抗肿瘤药物组合物及其制剂和应用
|
|
CN111558044B
(zh)
|
2020-06-01 |
2022-02-11 |
中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） |
一种包含舒尼替尼的药物组合物及其制剂和应用
|
|
CN111808821B
(zh)
|
2020-06-24 |
2022-06-14 |
南方医科大学珠江医院 |
Flt3-nkg2d双靶点car-t的构建与制备
|
|
WO2022009235A1
(en)
|
2020-07-10 |
2022-01-13 |
Msn Laboratories Private Limited, R&D Center |
Process for the preparation of gilteritinib fumarate
|
|
CN111760024B
(zh)
|
2020-07-24 |
2021-12-28 |
中国药科大学 |
一种渗透增强型金纳米簇载药靶向制剂及其制法和应用
|
|
EP4262802A4
(en)
|
2020-12-15 |
2024-11-13 |
Children's Hospital Medical Center |
MULTI-CYCLIC COMPOUNDS INHIBITING IRAK AND FLT3 AND THEIR USES
|
|
KR102231446B1
(ko)
|
2021-01-21 |
2021-03-24 |
(주) 와이디생명과학 |
베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
|
|
WO2022173021A1
(ja)
|
2021-02-12 |
2022-08-18 |
公益財団法人がん研究会 |
ギルテリチニブの種々の変異体に対する適用
|
|
CN115429805A
(zh)
|
2021-06-01 |
2022-12-06 |
上海交通大学医学院附属瑞金医院 |
一种抗flt3-itd耐药突变型急性髓系白血病药物
|
|
TW202317561A
(zh)
|
2021-07-01 |
2023-05-01 |
美商羅曼德生物治療公司 |
作為治療劑的具有１ｈ—吡唑并［４，３—ｃ］吡啶—６—胺基的化合物
|
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
|
EP4401735A4
(en)
|
2021-09-16 |
2025-07-16 |
Lomond Therapeutics Inc |
COMPOUNDS COMPRISING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS
|
|
CA3233245A1
(en)
|
2021-09-24 |
2023-03-30 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
CN113861179A
(zh)
|
2021-10-22 |
2021-12-31 |
上海应用技术大学 |
一种新型flt3激酶抑制剂及其合成与应用
|
|
WO2023116888A1
(zh)
|
2021-12-23 |
2023-06-29 |
杭州多域生物技术有限公司 |
一种五元并六元化合物、制备方法、药物组合物和应用
|
|
WO2023150601A2
(en)
|
2022-02-02 |
2023-08-10 |
Children's Hospital Medical Center |
Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
|
|
CN115710281B
(zh)
|
2022-11-14 |
2024-05-17 |
南京中医药大学 |
一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途
|